Editas Medicine presents new in vivo gene editing data on EDIT-401 at TIDES USA 2026 Meeting

Traders Union
All News
Companies
Editas debuts EDIT-401 at TIDES

Top Stories

Editors' Picks

Crypto

Financial News

Currencies

Market Voices

Companies

Regulators News

Central Banks News

13.05.2026

Editas Medicine presents new in vivo gene editing data on EDIT-401 at TIDES USA 2026 Meeting — Editas debuts EDIT-401 at TIDES

Editas Medicine announced the presentation of new insights on its lead in vivo development candidate, EDIT-401, during the TIDES USA 2026 Meeting.

The oral presentation highlights the company’s commitment to developing gene editing treatments for cardiovascular disease. Event participants can access additional details through the TIDES conference website.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Editas has previously shared preclinical data on gene editing at major scientific events, advancing cardiovascular research earlier this year. The company also recently announced its first quarter 2026 results and provided updates on its gene editing programs in a business update. These developments reflect Editas’s continued focus on its pipeline.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Did you like the article?

Editor's Picks for You

Bitcoin price prediction based on RSI: Is BTC poised for a new rally?

By Oleg Tkachenko
3 hours ago

Bitcoin price prediction based on RSI: Is BTC poised for a new rally?

Editors' Picks

Toncoin becomes Gram: Why Durov restored token's original name

By Anastasiia Chabaniuk
Yesterday

Toncoin becomes Gram: Why Durov restored token's original name

Editors' Picks

Why Tether flipping Ethereum is a pivotal moment for crypto

By Kyle Torpey
15.06.2026

Why Tether flipping Ethereum is a pivotal moment for crypto

Editors' Picks

All Editors' Top Picks

Latest Editas Medicine News

Editas Medicine CEO to join MIT panel on pipeline prioritization at Longwood Healthcare Leaders event

By Anastasiia Chabaniuk
12.06.2026

Editas Medicine CEO to join MIT panel on pipeline prioritization at Longwood Healthcare Leaders event

Companies

#Editas Medicine

Editas Medicine adjusts agenda at key investor event

By Mikhail Vnuchkov
28.05.2026

Editas Medicine adjusts agenda at key investor event

Companies

#Editas Medicine

Editas Medicine presents new preclinical data on EDIT-401 at EASCongress2026

By Anastasiia Chabaniuk
27.05.2026

Editas Medicine presents new preclinical data on EDIT-401 at EASCongress2026

Companies

#Editas Medicine

All Editas Medicine News

Oleg Tkachenko
3 hours ago

Bitcoin price prediction based on RSI: Is BTC poised for a new rally?

Anastasiia Chabaniuk
Yesterday

Toncoin becomes Gram: Why Durov restored token's original name

Kyle Torpey
15.06.2026

Why Tether flipping Ethereum is a pivotal moment for crypto

Eugene Komchuk
15.06.2026

MiCA deadline: Why crypto companies are leaving Europe

Mikhail Vnuchkov
13.06.2026

From “Holy Trinity” to WLD crash: How Arthur Hayes became a market-moving seller

Elena Nikulina
2 min ago

Andy Constan: Market for 6-12 month variance swaps on mega caps remains illiquid

Oleg Tkachenko
18 min ago

Eric Balchunas: Buffer ETFs expand globally as Europe gains traction

Daria Chernytska
27 min ago

Prediction markets become accessible to all on Sui Network, Adeniyi Abiodun notes

Ivan Andriyenko
42 min ago

Meb Faber: Compounding should not be interrupted unnecessarily

Mikhail Vnuchkov
53 min ago

Michael Pettis: USSR maximized output under soft budget constraints at expense of value

Weekly Top Bonuses

Capitalcore

up to $2,500
deposit bonus for all clients

Your capital is at risk.

Top News

Eugene Komchuk
1 hour ago

Traders Union research: 58% of crypto investors have encountered scams

Traders Union research: 58% of crypto investors have encountered scams

Parshwa Turakhiya
3 hours ago

Sam Bankman-Fried weighs token launch after prison sentence

Sam Bankman-Fried weighs token launch after prison sentence

Ivan Andriyenko
4 hours ago

U.S. futures rise before Fed rate decision

U.S. futures rise before Fed rate decision

Olga Shendetskaya
5 hours ago

Oil falls as Hormuz uncertainty keeps traders cautious

Oil falls as Hormuz uncertainty keeps traders cautious

Eugene Komchuk
5 hours ago

Binance risks losing access to EU market over MiCA license issues

Binance risks losing access to EU market over MiCA license issues

Top 5 companies for you

United States

Live News

Mykhailo Ihnatenko
Now

AMD rallies on AI growth as insider selling raises concerns

Anton Kharitonov
Now

Apple rebounds after selloff as AI strategy supports shares

Anton Kharitonov
Now

Bitcoin holds below $68,000 as market awaits signals from ETFs and Fed

Anton Kharitonov
Now

WTI updates local lows as returning supply and fading geopolitical risk premium weigh on prices

Mykhailo Ihnatenko
Now

Unilever balances AI ambitions and weak sales

© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186

Risk disclosure:

Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.
Disclaimer:

Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.
Disclosure of advertisers and revenues:

All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.